Status
Global HQ
Parkville, Australia
Countries of investment
Investment stages
Industries
About
SYNthesis BioVentures is a dedicated investment fund specializing in early-stage therapeutics, with a particular focus on small molecule therapeutics, biologics, and innovative cell and gene therapies that address significant unmet medical needs. By strategically investing in promising biotechnology ventures, SYNthesis BioVentures aims to bridge the funding gap within the Australian biotech ecosystem, fostering the development of groundbreaking solutions that can enhance patient outcomes. The firm is committed to supporting visionary entrepreneurs and pioneering research that has the potential to transform healthcare and improve lives. Through its comprehensive expertise and extensive network, SYNthesis BioVentures is poised to drive advancements in the biotech sector.
SYNthesis BioVentures is a dedicated investment fund specializing in early-stage therapeutics, with a particular focus on small molecule therapeutics, biologics, and innovative cell and gene therapies that address significant unmet medical needs. By strategically investing in promising biotechnology ventures, SYNthesis BioVentures aims to bridge the funding gap within the Australian biotech ecosystem, fostering the development of groundbreaking solutions that can enhance patient outcomes. The firm is committed to supporting visionary entrepreneurs and pioneering research that has the potential to transform healthcare and improve lives. Through its comprehensive expertise and extensive network, SYNthesis BioVentures is poised to drive advancements in the biotech sector.
Investment Thesis
Manager's Experience
With a robust background in venture capital, the fund manager has successfully led investments across biotechnology and life sciences, focusing primarily on early-stage opportunities. Active in North America and Europe, they have completed over 50 deals that emphasize a data-driven approach to identify transformative innovations. Their strategic style incorporates an operator-first perspective, facilitating engagements with portfolio companies to enhance growth. Notable exits highlight their ability to navigate complex markets, providing substantial returns while nurturing groundbreaking advancements in healthcare.